Fund Size Statistics - The top three equity ETF types by fund size change are: Scale Index ETF (¥15.406 billion), Cross-border Industry Index ETF (¥6.624 billion), and Strategy Index ETF (¥5.384 billion) [9] - The bottom three equity ETF types by fund size change are: Theme Index ETF (-¥26.004 billion), Cross-border Scale Index ETF (-¥1.807 billion), and Cross-border Theme Index ETF (¥0.203 billion) [9] - The top three equity ETF products by fund size change are: CSI 500 ETF (¥2.832 billion), Chemical ETF (¥2.386 billion), and HuShen 300 ETF (¥2.229 billion) [9] - The bottom three equity ETF products by fund size change are: Communication ETF (-¥30.885 billion), Non-ferrous Metals ETF (-¥3.932 billion), and Gold Stock ETF (-¥2.963 billion) [13] Market Outlook - The macro timing model for February 2026 has a score of 0, indicating a historical 78.57% probability of the full A index rising in the following month, with an average increase of 3.37% [23] - A-shares are expected to experience a short-term volatile market, influenced by liquidity from overseas markets and the recent AI bubble discussions affecting tech growth stocks [23] - The recommendation is to adopt a balanced ETF allocation strategy due to the anticipated short-term fluctuations in the market [60]

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown a slight increase in performance, with a closing rise of 0.79% and a trading volume of 849 million yuan on February 6, 2024 [1]. Group 1: Fund Overview - The Hong Kong Innovative Drug ETF (159567) was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1]. - As of February 5, 2024, the fund's total shares stood at 10.244 billion, with a total size of 7.906 billion yuan, reflecting a 2.36% decrease in shares and a 0.13% increase in size since December 31, 2023 [1]. Group 2: Liquidity and Trading Activity - Over the last 20 trading days, the cumulative trading amount for the ETF reached 21.573 billion yuan, with an average daily trading amount of 1.079 billion yuan [1]. - Since the beginning of the year, the ETF has recorded a cumulative trading amount of 29.237 billion yuan over 25 trading days, averaging 1.169 billion yuan per day [1]. Group 3: Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 56.50% during the management period [1]. Group 4: Top Holdings - The top holdings of the Hong Kong Innovative Drug ETF (159567) include: - CSPC Pharmaceutical Group (10.44% holding, 108 million shares, market value of 825 million yuan) [2] - BeiGene (9.91% holding, 4.8299 million shares, market value of 782 million yuan) [2] - CanSino Biologics (9.72% holding, 7.52 million shares, market value of 768 million yuan) [2] - China Biologic Products (9.66% holding, 13.7 million shares, market value of 763 million yuan) [2] - Innovent Biologics (9.53% holding, 10.9295 million shares, market value of 753 million yuan) [2] - Other notable holdings include 3SBio, Hansoh Pharmaceutical, and Kelun-Biotech [2].

Market Performance - The Hang Seng Index fell by 1.21%, closing at 26,559.95 points, with a total market turnover of HKD 2,478.65 million [1] Southbound Trading Data - Tencent Holdings received a net inflow of HKD 4.324 billion, while Alibaba-W and Southern Hang Seng Technology saw net inflows of HKD 1.656 billion and HKD 0.803 billion, respectively [1] - Conversely, SMIC, China Mobile, and WuXi Biologics experienced net outflows of HKD 0.835 billion, HKD 0.804 billion, and HKD 0.347 billion, respectively [1] Individual Stock Performance - Tencent Holdings: Trading volume of HKD 7.664 billion, net inflow of HKD 4.324 billion, closing price at HKD 547.50, down by 1.97% [1] - Alibaba-W: Trading volume of HKD 6.727 billion, net inflow of HKD 1.656 billion, closing price at HKD 155.00, down by 2.88% [1] - Southern Hang Seng Technology: Trading volume of HKD 3.526 billion, net inflow of HKD 0.803 billion, closing price at HKD 5.23, down by 0.95% [1] - Other notable stocks include Pop Mart with a net inflow of HKD 0.589 billion and a closing price of HKD 243.20, up by 0.33% [1]

Group 1 - On February 6, 2026, Alibaba-W (09988), Tencent Holdings (00700), and Yangtze Optical Fibre and Cable (06869) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 4.39 billion, 4.30 billion, and 2.05 billion respectively [1] - In the Southbound Stock Connect, Tencent Holdings (00700), Alibaba-W (09988), and Southern Hang Seng Technology (03033) were the top three companies by trading volume, with trading amounts of 3.37 billion, 2.34 billion, and 1.53 billion respectively [1] Group 2 - In the Southbound Stock Connect, the top active companies by trading amount included Alibaba-W (09988) with a net buy of 0.93 billion, Tencent Holdings (00700) with a net buy of 2.37 billion, and Yangtze Optical Fibre and Cable (06869) with a net buy of 0.12 billion [1] - In the Southbound Stock Connect, Tencent Holdings (00700) had a net buy of 1.95 billion, Alibaba-W (09988) had a net buy of 0.72 billion, and Southern Hang Seng Technology (03033) had a net buy of 0.80 billion [1]

Group 1 - On February 6, southbound funds recorded a net purchase of HKD 14.859 billion, with Tencent Holdings and Alibaba receiving net buys of HKD 4.324 billion and HKD 1.656 billion respectively [1] - Kangfang Biotech and Changfei Optical Fiber Cable experienced net sales of HKD 306 million and HKD 79 million respectively [1] - Tencent Holdings closed at HKD 547.50, down 1.97%, while Alibaba closed at HKD 155.00, down 2.88% [2][3] Group 2 - Tencent and Alibaba faced further restrictions on their AI applications, impacting their competitive positioning in the consumer AI sector [4] - Bubble Mart announced London as its European headquarters and plans to open seven new stores in the UK, creating over 150 jobs [4] - China National Offshore Oil Corporation (CNOOC) is expected to see a rebound in oil and industrial metal prices by 2026, despite current commodity market volatility [4] Group 3 - China Mobile, along with other major telecom operators, launched Beidou SMS services, which may help mitigate profit pressures from increased VAT rates [5] - Morgan Stanley maintains a positive outlook on China Mobile due to its high profit margins and attractive dividend yield [5]

Group 1 - Southbound funds recorded a net purchase of HKD 14.859 billion today [1] - Tencent Holdings received a net inflow of approximately HKD 4.324 billion [1] - Alibaba-W saw a net inflow of around HKD 1.656 billion [1] Group 2 - Kangfang Biopharmaceutical experienced a net outflow of HKD 306 million [1] - Changfei Optical Fiber (601869) faced a net outflow of HKD 79 million [1]

Group 1 - Southbound funds recorded a net purchase of approximately 148.59 billion HKD today [1] - Tencent Holdings received a net purchase of about 43.24 billion HKD, ranking first among the stocks [1] - Alibaba-W also saw a net purchase of approximately 16.56 billion HKD [1] Group 2 - Kangfang Biologics experienced a net sell-off of 3.06 billion HKD [1]

Group 1 - Southbound funds recorded a net purchase of 14.859 billion HKD, indicating strong investor interest in the Hong Kong market [1] - Tencent Holdings, Alibaba-W, and Southern Hang Seng Technology were the top three net purchases, with net inflows of 4.324 billion HKD, 1.656 billion HKD, and 0.803 billion HKD respectively [1] - On the sell side, Kangfang Biotech experienced a net sell of 0.306 billion HKD, while Changfei Optical Fiber Cable saw a net sell of 0.079 billion HKD [1]

Core Viewpoint - The article discusses the poor performance of actively managed equity funds established in 2021, with over 50% of them still showing negative returns despite the A-share market recovering above 4000 points [1]. Fund Performance Summary - A total of 667 actively managed equity funds established in 2021 were analyzed, revealing that approximately 362 funds have negative returns since inception, accounting for over 50% of the sample [1]. - Among these, 86 funds have experienced declines of over 30%, and 34 funds have seen declines exceeding 40% [1]. - Specific funds such as Qianhai Kaiyuan Public Health Theme Select and others have reported losses greater than 50% since their inception [1]. Specific Fund Data - Qianhai Kaiyuan Public Health Stock A/C, established on March 25, 2021, has a return of -57.80% and -58.60% as of February 5, 2026, with a cumulative loss nearing 60% [2]. - The fund's top ten holdings include companies like Tigermed, WuXi AppTec, and BeiGene [1]. - Qianhai Kaiyuan Public Health Stock A/C has a scale of 0.83 billion yuan as of December 31, 2025 [2]. Additional Fund Performance - Qianhai Kaiyuan Quality Enterprises 6-Month Holding Mixed A/C, established on January 8, 2021, has cumulative returns of -40.78% and -43.14% [3]. - The fund's top holdings include major companies such as Tencent and Alibaba, but its performance has been subpar since 2026 [4].

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Add" for 药明康德 (WuXi AppTec) [6][53]. Core Insights - The report highlights the recent approval of new drugs, including 埃诺格鲁肽注射液 (Energulutide Injection), which is the first of its kind approved for adult type 2 diabetes patients [16]. - The report emphasizes the importance of the recent policies from the National Medical Security Administration aimed at enhancing the medical insurance landscape, which is expected to improve service levels and create development opportunities in the industry [14]. - The report notes significant growth in product revenues for companies like 信达生物 (Innovent Biologics) and 康方生物 (CanSino Biologics), indicating a positive trend in the sector [31][32]. Industry News - The National Medical Security Administration issued a notice to accelerate the cultivation and application of new scenarios in the medical insurance field, which is expected to enhance service levels and create industry development opportunities [14]. - The Ministry of Industry and Information Technology, along with seven other departments, released a plan for the high-quality development of the traditional Chinese medicine industry from 2026 to 2030, aiming to strengthen the entire industry chain [15]. - The report mentions that in 2025, the employee medical insurance personal account had a total of 4.64 billion person-times, with a total amount of 68.77 billion yuan [15]. Company Announcements - 信达生物 (Innovent Biologics) reported a strong revenue growth of approximately 45% year-on-year for 2025, with a significant increase in Q4 revenue due to new drugs being included in the national medical insurance directory [31]. - 康方生物 (CanSino Biologics) granted exclusive commercialization rights for 伊喜宁® (Evinacumab) to 济川药业 (Jichuan Pharmaceutical), receiving an upfront payment of 80 million yuan [32]. - 恒瑞医药 (Hengrui Medicine) has had several drug applications accepted by the FDA and NMPA, indicating ongoing progress in its product pipeline [33]. Market Review - The report notes a decline in major indices, with the SW Pharmaceutical and Biological sector down by 0.97% during the week of January 30 to February 5, 2026 [45]. - The overall industry P/E ratio as of February 5, 2026, was reported at 51.01 times, with a valuation premium of 261% relative to the CSI 300 index [47]. Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring companies involved in small nucleic acids and AI applications [53].